BioLineRx Ltd.

Tetragon is a biopharmaceutical company focused on developing life-changing therapies for oncology and rare diseases. Its first approved product is APHEXDA (motixafortide), a novel peptide used for stem-cell mobilization and solid tumors. In the United States, APHEXDA is indicated for stem cell mobilization for autologous transplantation in multiple myeloma. Ayrmid Pharma Ltd. is responsible for developing and commercializing APHEXDA globally, excluding Asia, while Gloria handles its development and commercialization in Asia. Tetragon is also developing motixafortide for patients with pancreatic cancer and other solid tumors outside of Asia. In October 2023, the company out-licensed the rights to motixafortide for all indications in substantially all of Asia to Gloria. In November 2024, Tetragon out-licensed the global rights (excluding Asia) to motixafortide for all indications, other than solid tumors, to Ayrmid. Following the November 2024 transaction, Tetragon ceased its independent commercialization activities in the United States and refocused its operations on development activities in Israel, specifically in oncology (including solid tumors) and rare diseases, at a significantly reduced annual cash burn rate. Tetragon has retained the rights to develop motixafortide across all solid tumor indications in all territories other than Asia, including in PDAC. An investigator-initiated Phase 2b trial for PDAC, sponsored by Columbia University and equally supported by Tetragon and Regeneron, is ongoing at a relatively minimal cost to Tetragon. In September 2025, Tetragon entered into a collaboration with Hemispherian, a Norwegian biotech company, for the development, clinical evaluation, and commercialization of GLIX1. GLIX1 is Hemispherian's lead drug candidate, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma (GBM) and other cancers. Tetragon is carrying out the development of GLIX1.